Amexdrug Corporation (AXRX)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Jun 6, 2025
Amexdrug Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | 2003 - 2007 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '13 Jun 30, 2013 | Dec '12 Dec 31, 2012 | Dec '11 Dec 31, 2011 | Dec '10 Dec 31, 2010 | Dec '09 Dec 31, 2009 | Dec '08 Dec 31, 2008 | 2003 - 2007 |
| Revenue | 9.17 | 9.15 | 12.41 | 11.49 | 9.77 | 5.69 | Upgrade
|
| Revenue Growth (YoY) | -12.19% | -26.26% | 8.00% | 17.61% | 71.55% | -7.27% | Upgrade
|
| Cost of Revenue | 7.9 | 8.14 | 11.41 | 10.52 | 9.05 | 5.24 | Upgrade
|
| Gross Profit | 1.27 | 1.01 | 1 | 0.96 | 0.72 | 0.45 | Upgrade
|
| Selling, General & Admin | 0.88 | 0.79 | 0.77 | 0.66 | 0.53 | 0.36 | Upgrade
|
| Research & Development | - | - | - | - | 0.12 | 0.04 | Upgrade
|
| Operating Expenses | 0.93 | 0.81 | 0.77 | 0.67 | 0.67 | 0.42 | Upgrade
|
| Operating Income | 0.33 | 0.2 | 0.22 | 0.29 | 0.06 | 0.03 | Upgrade
|
| Interest Expense | -0.05 | -0.04 | -0.03 | -0.03 | -0.02 | -0.02 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0 | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | 0.28 | 0.16 | 0.19 | 0.27 | 0.03 | 0.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0 | 0 | -0 | -0 | -0 | -0 | Upgrade
|
| Other Unusual Items | - | - | -0 | - | -0 | -0 | Upgrade
|
| Pretax Income | 0.29 | 0.16 | 0.19 | 0.27 | 0.03 | 0.02 | Upgrade
|
| Income Tax Expense | 0.12 | 0.08 | 0.09 | 0.08 | 0.01 | 0 | Upgrade
|
| Earnings From Continuing Operations | 0.17 | 0.08 | 0.1 | 0.19 | 0.02 | 0.01 | Upgrade
|
| Net Income | 0.17 | 0.08 | 0.1 | 0.19 | 0.02 | 0.01 | Upgrade
|
| Net Income to Common | 0.17 | 0.08 | 0.1 | 0.19 | 0.02 | 0.01 | Upgrade
|
| Net Income Growth | 1354.56% | -18.49% | -46.77% | 930.54% | 48.77% | 7.83% | Upgrade
|
| Shares Outstanding (Basic) | 169 | 169 | 169 | 169 | 169 | 169 | Upgrade
|
| Shares Outstanding (Diluted) | 169 | 169 | 169 | 169 | 169 | 169 | Upgrade
|
| EPS (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Upgrade
|
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Upgrade
|
| EPS Growth | 1359.70% | -18.52% | -46.77% | 933.33% | 50.00% | 7.46% | Upgrade
|
| Free Cash Flow | -0.54 | -0.62 | -0.18 | 0.22 | -0.07 | -0.2 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | 0.00 | - | -0.00 | Upgrade
|
| Gross Margin | 13.80% | 11.00% | 8.03% | 8.38% | 7.39% | 7.98% | Upgrade
|
| Operating Margin | 3.61% | 2.14% | 1.78% | 2.53% | 0.57% | 0.58% | Upgrade
|
| Profit Margin | 1.81% | 0.90% | 0.81% | 1.65% | 0.19% | 0.22% | Upgrade
|
| Free Cash Flow Margin | -5.85% | -6.77% | -1.45% | 1.94% | -0.75% | -3.44% | Upgrade
|
| EBITDA | 0.38 | 0.22 | 0.23 | 0.3 | 0.06 | 0.05 | Upgrade
|
| EBITDA Margin | 4.15% | 2.35% | 1.84% | 2.60% | 0.66% | 0.89% | Upgrade
|
| D&A For EBITDA | 0.05 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | Upgrade
|
| EBIT | 0.33 | 0.2 | 0.22 | 0.29 | 0.06 | 0.03 | Upgrade
|
| EBIT Margin | 3.61% | 2.14% | 1.78% | 2.53% | 0.57% | 0.58% | Upgrade
|
| Effective Tax Rate | 42.03% | 48.63% | 46.16% | 28.88% | 32.57% | 27.85% | Upgrade
|
| Advertising Expenses | - | 0.03 | 0.01 | 0.01 | 0.02 | 0 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.